|
Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process. |
|
|
|
Consulting or Advisory Role - Celgene; Ipsen; Novartis |
Research Funding - BMS Brazil; Genentech; Ipsen; Lilly; Sirtex Medical |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Merck Serono; SERVIER |
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology |
|
|
No Relationships to Disclose |
|
|
Research Funding - Novartis (Inst); Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Sirtex Medical (Inst) |
Research Funding - Blueprint Medicines; Foundation Medicine; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Partnership for Health Analytic Research, LLC |
|
|
Honoraria - Advanced Accelerator Applications; AstraZeneca; Baxalta; Celgene; Ipsen; Lilly; Merck; Midatech Pharma; Novartis; Sirtex Medical |
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Baxalta; Celgene; Ipsen; Lilly; Merck; Novartis; Sirtex Medical |
Speakers' Bureau - Abbott Nutrition; Celgene; Ipsen; Novartis; Pfizer; Sirtex Medical |
Research Funding - AstraZeneca (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Celgene; Novartis |